Medical imaging is increasingly important for understanding diseases, detecting them early, and personalizing treatments. New imaging techniques, which can measure processes in the body without surgery, are opening the door to a more precise approach to medicine. Instead of relying on general probabilities, this technology allows us to analyze specific factors in a person's health, leading to better predictions and targeted treatments. One key challenge in medicine today is reducing "residual individual risk"-the remaining health risks that current treatments don't fully address. This involves understanding how factors like age, sex, genetics, and environment affect our health, particularly when it comes to conditions like heart and liver disease. By using imaging to distinguish between normal aging and disease, we can better assess individual health risks. The current project will create a large collection of medical images linked with health data from a broad population across France. Using advanced, non-invasive techniques such as MRI and ultrasound, researchers will analyze the heart, blood vessels, and liver in detail, considering factors like gender and health risk profiles. This will help improve our understanding of these diseases, which are often silent and not well understood, providing direct benefits to the participants. Ultimately, the goal is to optimize imaging technologies for large-scale studies, which will help enhance early detection and prevention for everyone.
Study Type
OBSERVATIONAL
Enrollment
2,400
* Cardiovascular MRI * Hepatic MRI * Hepatic ultrasound
* Urinary pregnancy test for women of childbearing age. * Blood sample for cardiometabolism profiling * Blood samples for biobanking (according to the information and consent form) * Impedancemetry * AGE reader: combined non-invasive measurement of aging and accumulation of glycated proteins in the subcutaneous tissue will be performed with a CE-marked device.
* Review of risk factors * Review of previous history * Recording of current medication (dci, dose, start date) * Recording of medication in the last 6 months and discontinued since (dci, dose, start date)
Echocardiography including: 12-lead digital ECG
Hôpital Pitié-Salpêtrière
Paris, France
RECRUITINGEstablishement of reference nomograms accounting for age in heart
Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
Time frame: During 36 months of analysis (after 60 months of inclusion)
Establishement of reference nomograms accounting for sex in heart
Ultrasound and MRI images analysis of qualitative and quantitative morphology, function, quantitative tissue characterization of the heart
Time frame: During 36 months of analysis (after 60 months of inclusion)
Establishement of reference nomograms accounting for age in liver
Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
Time frame: During 36 months of analysis (after 60 months of inclusion)
Establishement of reference nomograms accounting for sex in liver
Ultrasound and MRI images analysis of quantitative steatosis, fibrosis
Time frame: During 36 months of analysis (after 60 months of inclusion)
Establishement of reference nomograms accounting for age in adipose tissue
Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
Time frame: During 36 months of analysis (after 60 months of inclusion)
Establishement of reference nomograms accounting for sex in adipose tissue
Ultrasound and MRI images analysis of volumes of subcutaneous, visceral and epicardial adipose tissues
Time frame: During 36 months of analysis (after 60 months of inclusion)
Advanced Imaging profiling of Heart
Analysis of the cardiac cavities in 2D, 3D and in deformation by echocardiography analysis
Time frame: During 36 months of analysis (after 60 months of inclusion)
Advanced imaging profiling in Liver
Qualitative analysis of liver morphology and the nodularity of its boundaries, presence of ascites and portal derivation. Also presence of incidentaloma.
Time frame: During 36 months of analysis (after 60 months of inclusion)
Advanced biological phenotyping
Study of metabolic pathways and candidate biomarker suspected to be involved in aging
Time frame: During 36 months of analysis (after 60 months of inclusion)
identification of genetic risk markers for cardio-metabolic diseases
Defining the minimum set of markers useful for creating a risk score
Time frame: During 36 months of analysis (after 60 months of inclusion)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.